Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Debt-to-EBITDA : -1.02 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Chongqing Genrix Biopharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥12.17 Mil. Chongqing Genrix Biopharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥630.12 Mil. Chongqing Genrix Biopharmaceutical Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥-626.95 Mil. Chongqing Genrix Biopharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -1.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:688443' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.31 Med: -1.6 Max: -0.88
Current: -0.88

During the past 5 years, the highest Debt-to-EBITDA Ratio of Chongqing Genrix Biopharmaceutical Co was -0.88. The lowest was -2.31. And the median was -1.60.

SHSE:688443's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs SHSE:688443: -0.88

Chongqing Genrix Biopharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Debt-to-EBITDA Chart

Chongqing Genrix Biopharmaceutical Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-2.10

-1.15

-2.31

-1.60

-0.91

Chongqing Genrix Biopharmaceutical Co Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial								-1.12	-1.27	-0.94	-0.71	-1.02

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA falls into.

Chongqing Genrix Biopharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(10.696	+	630.296)	/	-707.167
	=	-0.91

Chongqing Genrix Biopharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(12.169	+	630.12)	/	-626.948
	=	-1.02

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Chongqing Genrix Biopharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338

Website

http://www.genrixbio.com

Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

Executives

Jiang Ren Sheng

Director

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Headlines

No Headlines